Long Ideas - Palifosfamide is a bifunctional alkylator developed by Ziopharm Oncology (NASDAQ:ZIOP) for the treatment of a number of cancers. Soft tissue sarcoma (STS) is the most … Continue Reading
Read NowResearch - We continue to believe that shares of Elan Corp. (NYSE:ELN) are trading at a premium valuation, given ongoing speculation that partner Biogen-Idec (NASDAQ:BIIB) may acquire … Continue Reading
Read NowLong Ideas - Huntington’s disease is an inherited neurodegenerative disorder that leads to the progressive degeneration of nerve cells in the brain. The disease is genetic in nature … Continue Reading
Read NowLong Ideas - After being decimated earlier this year on the FDA rejection of Northera, shares of Chelsea Therapeutics (NASDAQ:CHTP) could be rejuvenated as new Phase III results … Continue Reading
Read NowLong Ideas - On Tuesday, Gattex (teduglutide) received a unanimous recommendation for approval from the FDA’s Gastrointestinal Drugs Advisory Committee, suggesting that the FDA may officially approve the … Continue Reading
Read NowResearch - Amedisys, Inc. (NASDAQ:AMED) took a 9% hit Monday, as the company announced a major restructuring of its home health services agreement with Humana (NYSE:HUM). HUM … Continue Reading
Read NowLong Ideas - Exelixis (NASDAQ:EXEL) has a Prescription Drug User Fee Act (PDUFA) action date on November 29th, 2012 for cabozantinib as a treatment for patients with progressive, unresectable, … Continue Reading
Read Now